Scientific Advisory Board
Cardiovascular Health Experts
Christie M. Ballantyne, M.D.
Dr. Ballantyne is a leading cardiovascular specialist, lipidology expert and atherosclerotic vascular disease researcher. He is currently a Professor of Medicine at Baylor College of Medicine and the Chief of the Sections of Cardiovascular Research and Cardiology. Additionally, Dr. Ballantyne is the Director of The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory and the Director of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart and Vascular Center as well as the Co-Director of the Lipid Metabolism and Atherosclerosis Clinic at Houston Methodist Hospital.
Dr. Ballantyne has conducted extensive research on the pathophysiology of atherosclerosis, with an emphasis on monocyte activation and adhesion, and led numerous clinical research programs on the prevention of atherosclerotic vascular disease. Dr. Ballantyne earned his degree in medicine from Baylor College of Medicine and performed both his internal medicine residency and postgraduate training at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at Baylor College of Medicine and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor. Dr. Ballantyne is published extensively, speaks nationally and internationally on lipids, atherosclerosis and inflammation, and serves as an Editorial Director for www.lipidsonline.org. In 2014, he was recognized by Thomson Reuters as one of The World's Most Influential Scientific Minds.
John J.P. Kastelein, M.D., Ph.D., FESC
Dr. John Kastelein is Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. Dr. Kastelein is a recognized world leader in studies focused on the significance of lipoprotein metabolism in the development of atherosclerotic vascular disease. Dr. Kastelein's current research interests focus on the etiology, diagnosis, prevention, and treatment of hypertriglyceridemia, hypercholesterolemia, and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. He has published more than 850 research papers in peer-reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA, and Circulation. His Hirsch index is 114 as of March 2018; and his total citations are approaching more than 60,000.
Dr. Kastelein founded the Lipid Research Clinic at the Academic Medical Centre in Amsterdam in 1989, which is currently serving as a tertiary referral center for over 5000 patients each year and has become part of the Department of Vascular Medicine. Dr. Kastelein was President of the Dutch Atherosclerosis Society (DAS) and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society, and a Fellow of the European Society of Cardiology. He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS). In addition to the scientific programs aimed at the etiology of atherogenesis, Dr. Kastelein also served on a number of executive and steering committees of large cardiovascular intervention studies, including the SPIRE, ORION, GLAGOV, REALIZE, IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008), JUPITER (2008), SPIRE and ORION (2017) are published in the New England Journal of Medicine, IDEAL (2006) and GLAGOV (2017) in JAMA and RADIANCE 2 (2007) and REALIZE (2016) in Lancet.
Kevin C. Maki, Ph.D.
Dr. Kevin Maki is a leading clinical lipid specialist with extensive experience in the design and conduct of clinical trials in human nutrition, metabolism and chronic disease management. He has participated in more than 250 clinical trials and observational studies as an investigator, consultant or statistician. Dr. Maki is the Founder and Chief Scientist for the Midwest Biomedical Research Center for Metabolic and Cardiovascular Health and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University in Chicago. He is a certified Clinical Lipid Specialist and a Fellow of the National Lipid Association, The Obesity Society and the American College of Nutrition, as well as a Vice President of the Board of Governors of the Accreditation Council for Clinical Lipidology.
Dr. Maki's research has been extensively published in more than 200 peer reviewed scientific papers and he has authored or co-authored several books, including Practical Lipid Management: Concepts and Controversies and Therapeutic Lipidology. He also served as a member of the Expert Panel and Writing Group that developed the National Lipid Association's Recommendations for Patient-Centered Management of Dyslipidemia: Parts 1 and 2.
Harold E. Bays, M.D.
Dr. Bays is Board Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Clinical Lipidology, and Diplomate of the American Board of Obesity Medicine. He is the Founder of Your Body Goal, where he oversees a state-of-the art weight management program and also serves as Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center. He has written or served as a contributing author to over 200 peer-reviewed scientific manuscripts and book chapters, well as presented over 100 scientific abstracts at major scientific meetings and is frequently invited as a national and international speaker. He has served as first author for a number of scientific consensus statements in Lipidology and Obesity Medicine and was lead author of the National Lipid Association Annual Summary of Clinical Lipidology 2015 & 2016, co-author of the National Lipid Association Recommendations for Patient-Centered Treatment of Dyslipidemia, and Chairman of the Obesity Medicine Association Obesity Algorithm.
Over the course of his career, Dr. Bays has served as an Investigator for over 500 early to late-stage clinical trials evaluating treatments for dyslipidemias, obesity, diabetes mellitus, hypertension, and other metabolic and hormonal disorders. He served as Chairman of the National Lipid Association 2012 Adiposity and Dyslipidemia Consensus Conference and Chairman of the 2010 American Association of Clinical Endocrinologist Adipose Tissue Pathophysiology State of the Science Conference. He has served as Chairman and task force member for a number of other medical initiatives regarding lipids and obesity and has received several scientific awards in such as the 2016 Obesity Medicine Association "Obesity Medicine Clinician of the Year," 2015 National Lipid Association "President's Service Award," and 2014 American Society of Bariatric Physicians "Task Force Award."
Dr. Bays is a Fellow of the National Lipid Association (FNLA), Fellow of The Obesity Society (FTOS), Fellow of the American College of Cardiology (FACC) and Fellow of the American Association of Clinical Endocrinologists (FACE).
James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC, FNLA
Dr. Underberg is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg holds joint appointments in the divisions of General Internal Medicine and Endocrinology at NYU.
Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and Immediate Past-President of the National Lipid Association. He is a Fellow of the National Lipid Association and President of the American Board of Clinical Lipidology. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the National Lipid Association, the Foundation of the National Lipid Association, The American Society of Preventive Cardiology and the American Board of Clinical Lipidology. Dr. Underberg also serves on the scientific advisory board of the Familial Hypercholesterolemia (FH) Foundation.
Dr. Underberg's clinical focus is preventive cardiovascular medicine, where he specializes in the management of patients with lipids and lipoprotein disorders, hypertension management, and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology. Dr. Underberg has a Bachelor of Science and Master of Science from Yale University, and a medical degree from the Perelman School of Medicine at the University of Pennsylvania. His internship and residency were completed at Bellevue Hospital Medical Center.
Infectious Disease Experts
J. Carl Craft, M.D.
Infectious Disease Chair
Dr. J. Carl Craft was the Chief Executive Officer and Chief Medical Officer of Aquarius Biotechnologies from 2012 until its merger with Matinas BioPharma in 2015. From 2002 to 2007, he was Chief Scientific Officer for Medicines for Malaria Venture (MMV) in Geneva, which had the largest ever anti-malarial drug development portfolio, with 20 programs, of which three were in Phase 3 clinical trials. Prior to this, Dr. Craft worked at Abbott Laboratories as the "Venture Head" of the Anti-Infective Development Group for more than 15 years. Earlier in his career, he was at Tulane University in the Department of Pediatrics Infectious Diseases and Department of Pathology, where he was the Director of Pediatric Closed at the Care Charity Hospital of New Orleans and Director of The Clinical Microbiology Laboratory Tulane Medical Center. He served for two years in the Navy with a rank of Lieutenant Commander and was Chief of Pediatrics at the U.S. Naval Regional Medical Center, Guam, M.I. Dr. Craft serves on the Scientific Advisory Boards for CEMPRA, Drugs for Neglected Disease Institute (DNDi), and ANACOR BMG. He was a Research Fellow in Pediatric Infectious Diseases at The University of Texas, Southwestern Medical School under Drs. John Nelson and George McCracken. He did his residency in Pediatrics at Milwaukee Children's Hospital. He received his M.D. from The George Washington University, Medical School.
Prof. Oliver Cornely, M.D., FACP, FIDSA
Dr. Cornely is Professor of Internal Medicine and Attending Physician at the 1st Department of Internal Medicine, and Medical Director of the Center of Clinical Trials (ZKS) at the Medical Faculty, both located at the Uniklinik Köln, Cologne, Germany. Dr. Cornely received his medical degree from the University Hospital at Albertus Magnus University, Cologne, in 1994, where he also completed his residency. He then became an intern at the St. Katharinen Hospital, Frechen, Germany. He passed the Board Examinations in internal medicine, infectious diseases, haematology/oncology, and emergency medicine. Originating from an HIV/AIDS clinical research group, Dr. Cornely’s research interests include invasive fungal diseases in haematology/oncology and in the ICU setting. Dr Cornely is also a clinical infectious diseases consultant at the University Hospital of Cologne. Dr Cornely was recently elected President of the European Confederation of Medical Mycology for a 3-year term. He is past-President of the German-speaking Mycological Society, reviewer for numerous international journals, editorial board member for international journals such as Haematologica, Infectious Disease and Clinical Investigation, Editor in Chief of Mycoses, and a sought after invited speaker at numerous international and national conferences and popular workshop leader.
Dimitrios P. Kontoyiannis, M.D., M.S., Sc.D., PhD (Hon),FACP, FIDSA, FECMM
Dr Dimitrios P. Kontoyiannis received his medical degree Summa Cum Laude from the National and Kapodistrian University of Athens in Greece. He then did a post-doctoral clinical research fellowship in Mycology at the Section of Infectious Diseases at The University of Texas MD Anderson Cancer Center in Houston, TX, followed by training in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. He is currently the Director of the Mycology Research Program and Professor in the Department of Infectious Diseases Infection Control and Employee Health at The University of Texas MD Anderson Cancer Center. He is also an adjunct professor at the University of Houston College of Pharmacy. He serves as an associate editor for Medical Mycology and sits in the editorial Boards of Antimicrobial Agents & Chemotherapy, Medical Mycology and Transplantation Infectious Diseases and he is a reviewer in several peer-reviewed journals in Infectious Diseases, Oncology and Hematology. He has authored more than 170 peer-reviewed manuscripts and over 30 invited articles and book chapters.
Peter G. Pappas, M.D., FACP
Dr. Pappas is the William E. Dismukes Professor of Medicine in the Division of Infectious Diseases in the Department of Medicine at the University of Alabama at Birmingham, and the Principal Investigator for the Mycoses Study Group Education and Research Consortium (MSGERC) which performs multicenter trials, creates treatment guidelines for invasive mycoses, and coordinates training in the epidemiology, diagnosis and treatment of invasive mycoses. He is an internationally recognized expert in the treatment and diagnosis of invasive fungal infections with expertise in the development of new therapies for fungal infections and understanding the epidemiology of candidiasis, the endemic mycoses, and cryptococcosis. Over the last 25 years, Dr. Pappas has led numerous clinical trials in candidiasis, cryptococcosis, aspergillosis, sporotrichosis, blastomycosis, and histoplasmosis through his involvement with the National Institute of Allergy and Infectious Disease (NIAID) Bacteriology and Mycology Study Group (BAMSG) and the MSGERC. Dr. Pappas was the principal investigator of a national network of transplant centers, TRANSNET, a collaborative effort of the Centers for Disease Control and Prevention (CDC) and a consortium of industry co-sponsors to provide important epidemiologic and treatment information to transplant recipients who develop proven and probable invasive fungal infections. He is also the co-principal investigator of the Organ Transplant Infection Detection and Prevention Program (OTIP), a collaborative multicenter group funded by the CDC. Dr. Pappas joined the faculty at the University of Alabama in Birmingham School of Medicine in 1988, with a focus on HIV and transplant-associated opportunistic infections, especially the invasive mycoses. Previously, he was on the clinical faculty at the University of North Carolina School of Medicine in Chapel Hill, NC, through its affiliated hospital in Wilmington, North Carolina. Dr. Pappas earned his medical degree in 1978 from the University of Alabama School of Medicine in Birmingham. He completed his residency in internal medicine, chief medical residency, and infectious diseases fellowship at the University of Washington in Seattle.
David S. Perlin, Ph.D.
Dr. Perlin is Executive Director of the Public Health Research Institute (PHRI) and the Rutgers Regional Biocontainment Laboratory (RBL) of New Jersey Medical School (NJMS), Rutgers Biomedical and Health Sciences. He is also a Professor of Microbiology, Biochemistry and Molecular Genetics at NJMS. Dr. Perlin is an internationally recognized expert and research scientist in infectious diseases who has played a major role in advancing the national research agenda in biodefense and emerging infectious diseases. His primary expertise is in fungal infections, mechanisms of antifungal drug resistance, and rapid diagnosis of opportunistic drug resistant bacterial and fungal pathogens in high-risk patients. Dr. Perlin is the editor-in-chief of the new open access "Journal of Fungi." He serves on the Board of Directors of the Aaron Diamond AIDS Research Center, and on advisory boards and committees for the Clinical and Laboratory Standards Institute (CLSI), Leading International Fungal Education (LIFE), various pharmaceutical and biotech companies, PinnacleCare and the American Society for Microbiology (ASM). Dr. Perlin also serves on advisory and planning boards for several major international conferences, and he is a member of the Steering Committee for Microbiology, Immunology & Infectious Diseases of the New York Academy of Sciences. He earned a Ph.D. from Cornell University and pursued postdoctoral studies at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry. Dr. Perlin was named a Fellow of the New York Academy of Sciences in 2005, and a Visiting Professor at the University of Manchester, UK in 2009.